Pulmonary Congestion During Exercise Stress Echocardiography in Ischemic and Heart Failure Patients.

coronary artery disease echocardiography heart failure hypertension lung stress echocardiography

Journal

Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935

Informations de publication

Date de publication:
05 2022
Historique:
entrez: 17 5 2022
pubmed: 18 5 2022
medline: 20 5 2022
Statut: ppublish

Résumé

Lung ultrasound detects pulmonary congestion as B-lines at rest, and more frequently, during exercise stress echocardiography (ESE). We performed ESE plus lung ultrasound (4-site simplified scan) in 4392 subjects referred for semi-supine bike ESE in 24 certified centers in 9 countries. B-line score ranged from 0 (normal) to 40 (severely abnormal). Five different populations were evaluated: control subjects (n=103); chronic coronary syndromes (n=3701); heart failure with reduced ejection fraction (n=395); heart failure with preserved ejection fraction (n=70); ischemic mitral regurgitation ≥ moderate at rest (n=123). In a subset of 2478 patients, follow-up information was available. During ESE, B-lines increased in all study groups except controls. Age, hypertension, abnormal ejection fraction, peak wall motion score index, and abnormal heart rate reserve were associated with B-lines in multivariable regression analysis. Stress B lines (hazard ratio, 2.179 [95% CI, 1.015-4.680]; B-lines identify the pulmonary congestion phenotype at rest, and more frequently, during ESE in ischemic and heart failure patients. Stress B-lines may help to refine risk stratification in these patients. URL: https://www. gov; Unique identifier: NCT03049995.

Sections du résumé

BACKGROUND
Lung ultrasound detects pulmonary congestion as B-lines at rest, and more frequently, during exercise stress echocardiography (ESE).
METHODS
We performed ESE plus lung ultrasound (4-site simplified scan) in 4392 subjects referred for semi-supine bike ESE in 24 certified centers in 9 countries. B-line score ranged from 0 (normal) to 40 (severely abnormal). Five different populations were evaluated: control subjects (n=103); chronic coronary syndromes (n=3701); heart failure with reduced ejection fraction (n=395); heart failure with preserved ejection fraction (n=70); ischemic mitral regurgitation ≥ moderate at rest (n=123). In a subset of 2478 patients, follow-up information was available.
RESULTS
During ESE, B-lines increased in all study groups except controls. Age, hypertension, abnormal ejection fraction, peak wall motion score index, and abnormal heart rate reserve were associated with B-lines in multivariable regression analysis. Stress B lines (hazard ratio, 2.179 [95% CI, 1.015-4.680];
CONCLUSIONS
B-lines identify the pulmonary congestion phenotype at rest, and more frequently, during ESE in ischemic and heart failure patients. Stress B-lines may help to refine risk stratification in these patients.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT03049995.

Identifiants

pubmed: 35580160
doi: 10.1161/CIRCIMAGING.121.013558
doi:

Banques de données

ClinicalTrials.gov
['NCT03049995']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e013558

Commentaires et corrections

Type : CommentIn

Auteurs

Elisa Merli (E)

Department of Cardiology, Ospedale per gli Infermi, Faenza, Italy (E.M.).

Quirino Ciampi (Q)

Cardiology Division, Fatebenefratelli Hospital, Benevento, Italy (Q.C.).

Maria Chiara Scali (MC)

Cardiology Division, Campostaggia Hospital, Siena, Italy (M.C.S.).

Angela Zagatina (A)

Cardiology Department, Saint Petersburg State University Hospital, Saint Petersburg, Russian Federation (A.Z.).

Pablo Martin Merlo (PM)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina (P.M.M., R.A., J.L.).

Rosina Arbucci (R)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina (P.M.M., R.A., J.L.).

Clarissa Borguezan Daros (CB)

Cardiology Division, Hospital San José, Criciuma, Brasil (B.D.).

José Luis de Castro E Silva Pretto (JL)

Hospital Sao Vicente de Paulo e Hospital de Cidade, Passo Fundo, Brasil (J.L.d.C.e.S.P.).

Miguel Amor (M)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina (M.A., M.F.S., H.M.).

Michael F Salamè (MF)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina (M.A., M.F.S., H.M.).

Hugo Mosto (H)

Cardiology Department, Ramos Mejia Hospital, Buenos Aires, Argentina (M.A., M.F.S., H.M.).

Doralisa Morrone (D)

Cardiology Department, Cisanello University Hospital, Pisa, Italy (D.M.).

Antonello D'Andrea (A)

Cardiology, Monaldi Hospital, Second University of Naples, and Nocera Inferiore, Italy (A.D.).

Barbara Reisenhofer (B)

Cardiology Division, Pontedera Hospital, Pontedera, Italy (B.R.).

Hugo Rodriguez-Zanella (H)

Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico (H.R.-Z.).

Karina Wierzbowska-Drabik (K)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland (K.W.-D., J.D.K.).

Jaroslaw D Kasprzak (JD)

Chair of Cardiology, Bieganski Hospital, Medical University, Lodz, Poland (K.W.-D., J.D.K.).

Gergely Agoston (G)

Institute of Family Medicine, University of Szeged, Hungary (G.A., A.V.).

Albert Varga (A)

Institute of Family Medicine, University of Szeged, Hungary (G.A., A.V.).

Jorge Lowenstein (J)

Cardiodiagnosticos, Investigaciones Medicas, Buenos Aires, Argentina (P.M.M., R.A., J.L.).

Claudio Dodi (C)

Cardiology Department, Ospedale di Cremona, Italy (C.D.).

Lauro Cortigiani (L)

Cardiology Department, San Luca Hospital, Lucca, Italy (L.C.).

Iana Simova (I)

Cardiology Department, Heart and Brain Center of Excellence, University Hospital, Pleven, Bulgaria (I.S., M.S.).
Medical University, Pleven, Bulgaria (I.S., M.S.).

Martina Samardjieva (M)

Cardiology Department, Heart and Brain Center of Excellence, University Hospital, Pleven, Bulgaria (I.S., M.S.).
Medical University, Pleven, Bulgaria (I.S., M.S.).

Rodolfo Citro (R)

Cardio-Thoracic-Vascular-Department, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy (R.C.).

Jelena Celutkiene (J)

Centre of Cardiology and Angiology, Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Lithuania (J.C.).

Federica Re (F)

Ospedale San Camillo, Cardiology Division, Rome, Italy (F.R.).

Ines Monte (I)

Cardio-Thorax-Vascular Department, Echocardiography Lab, "Policlinico Vittorio Emanuele", Catania University, Italy (I.M.).

Suzana Gligorova (S)

Divisione Cardiologia, Ospedale Casilino, Rome, Italy (S.G.).

Francesco Antonini-Canterin (F)

Highly Specialized Rehabilitation Hospital Motta di Livenza, Cardiac Prevention and Rehabilitation Unit, Treviso, Italy (F.A.-C.).

Mauro Pepi (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy (M.P.).

Clara Carpeggiani (C)

Institute of Clinical Physiology, CNR, Pisa Italy (C.C., E.P.).

Patricia A Pellikka (PA)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (P.A.P.).

Eugenio Picano (E)

Institute of Clinical Physiology, CNR, Pisa Italy (C.C., E.P.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH